Nine Patients Received a Personalized Kidney Cancer Vaccine. None Had a Recurrence.
6 Articles
6 Articles
In a SMALL clinical trial, nine kidney cancer patients received a personalized vaccine. After three years of follow-up, no one had a relapse of the disease, which indicates promising results.
Nine Patients Received a Personalized Kidney Cancer Vaccine. None Had a Recurrence.
(Catherine Falls Commercial/Moment/Getty Images) Encouraging early results.ScienceAlert stories are written, fact-checked, and edited by humans, never generated by AI. Don't miss a story, subscribe here.
Personalized cancer vaccine shows results: Patients build immune response to cancer cells - All nine patients developed an immune response, and in seven of them, T-cells activated by the vaccine were able to recognize the patient's own tumor
In a small clinical trial of a personalized kidney cancer vaccine, none of the nine patients who received it experienced a recurrence of the disease. Participants were followed for an average of three years and four months after surgery, and the results are considered encouraging, although due to the small number of participants, it cannot be said with certainty that the vaccine prevented the disease from returning, reports Index.hr.
Breakthrough in the fight against kidney cancer
Coverage Details
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
